Altering Gene Expression in Modified T Cells and Uses Thereof
AssigneeThe Trustees of the University of Pennsylvania
InventorsYangbing ZHAO, Jiangtao REN, Xiaojun LIU, Carl H. JUNE
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR α chain, TCR β chain, beta-2 microglobulin and FAS further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.
Claims47
A modified T cell comprising:
- a nucleic acid capable of downregulating gene expression of an endogenous gene selected from the group consisting of TCR α chain, TCR β chain, beta-2 microglobulin, a HLA molecule, CTLA-4, PD1, and FAS;
- and
- a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell.
A method for generating a modified T cell comprising:
- introducing a nucleic acid capable of downregulating gene expression of an endogenous gene selected from the group consisting of TCR α chain, TCR β chain, beta-2 microglobulin, a HLA molecule, CTLA-4, PD1, and FAS into a T cell;
- and
- introducing a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell into the T cell.
Dependencies are inferred from the claim text.